참고문헌
- World Health Organization (2020) https://www.who.int/emergencies/diseases/novel-coronavirus-2019 (accessed on 21 April, 2020)
- Balachandar V, Kaavya J, MahalaxmiI et al (2020) COVID-19: A promising cure for the global panic. Sci Total Environ [Online ahead of print]
- Zheng F, Tang W, Li H, Huang Y, Xie Y, and Zhou Z (2020) Clinical characteristics of 161 cases of corona virus disease 2019 (COVID-19) in Changsha. Eur Rev Med Pharmacol Sci 24, 3404-3410
- Balachandar V, Mahalaxmi I, Kaavya J et al (2020) COVID-19: Emerging protective measures. Eur Rev Med Pharmaco 24, 3422-3425
- Rothe C, Schunk M, Sothmann P et al (2020) Transmission of 2019-nCoV infection from an asymptomatic contact in Germany. N Engl J Med 382, 970-971 https://doi.org/10.1056/NEJMc2001468
- Callaway E and Cyranoski D (2020) China coronavirus: six questions scientists are asking. Nature 577, 605-607 https://doi.org/10.1038/d41586-020-00166-6
- Huang C, Wang Y, Li X et al (2020) Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 395, 497-506 https://doi.org/10.1016/s0140-6736(20)30183-5
- Centers for Disease Prevention and Control (CDC) (2020) Interim guidelines for collecting, handling, and testing clinical specimens from persons for coronavirus disease 2019 (COVID-19). https://www.cdc.gov/coronavirus/2019-nCoV/lab/guidelines-clinical-specimens.html (accessed on 16 April, 2020)
- World Health Organization (WHO) (2020) Advice on the use of point-of-care immunodiagnostic tests for COVID-19 https://www.who.int/news-room/commentaries/detail/advi ce-on-the-use-of-point-of-care-immunodiagnostic-tests-forcovid-19. (accessed on 21 April, 2020)
- Indian Council of Medical Research (ICMR) (2020) https://icmr.nic.in/sites/default/files/upload_documents/Validatio n_of_Commercial_Kits_02042020.pdf (accessed on 16 April, 2020)
- World Health Organization (WHO) (2020) Coronavirus disease (COVID-19) technical guidance: Laboratory testing for 2019-nCoV in humans https://www.who.int/emergencies/diseases/novel-coronavirus-2019/technical guidance/laboratoryguidance (accessed on 21 April, 2020)
- Cao Y, Liu X, Xiong L, Cai K (2020) Imaging and clinical features of patients with 2019 novel coronavirus SARSCoV-2: a systematic review and meta-analysis. J Med Virol [Online ahead of print]
- Zhou F, Yu T, Du R et al (2020) Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet 395, 1054-1062 https://doi.org/10.1016/s0140-6736(20)30566-3
- Cao J, Tu WJ, Cheng W, Yu L, Tu W J, and Liu Q (2020) Clinical features and short-term outcomes of 102 patients with corona virus disease 2019 in Wuhan, China. Clin Infect Dis [Online ahead of print]
- World Health Organization (WHO) (2020) "Solidarity" clinical trial for COVID-19 treatments. https://www.who. int/emergencies/diseases/novel-coronavirus-2019/global-re search-on-novel-coronavirus-2019-ncov/solidarity-clinicaltrial- for-covid-19-treatments (accessed on 16 April, 2020)
- Stebbing J, Phelan A, Griffin I, Tucker C, Oechsle O, Smith D and Richardson P (2020) COVID-19: combining antiviral and anti-inflammatory treatments. Lancet Infect Dis 20, 400-402 https://doi.org/10.1016/s1473-3099(20)30132-8
- Bethesda, LiverTox: Clinical and Research Information on Drug-Induced liver injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012-. 2017 Feb 2
- Plantone D and Koudriavtseva T (2018) Current and future use of chloroquine and hydroxychloroquine in infectious, immune, neoplastic and neurological diseases: A Mini-Review. Clin Drug Investig 38, 653-671 https://doi.org/10.1007/s40261-018-0656-y
- Yan Y, Zou Z, Sun Y et al (2013) Anti-malaria drug chloroquine is highly effective in treating avian influenza A H5N1 virus infection in an animal model. Cell Res 23, 300-302 https://doi.org/10.1038/cr.2012.165
- Li C, Zhu X, Ji X et al (2017) Chloroquine, a FDA-approved drug, prevents Zika virus infection and its associated congenital microcephaly in mice. EBioMedicine 24, 189-194 https://doi.org/10.1016/j.ebiom.2017.09.034
- Shiryaev SA, Mesci P, Pinto A et al (2017) Repurposing of the anti-malaria drug chloroquine for Zika virus treatment and prophylaxis. Sci Rep 7, 15771 https://doi.org/10.1038/s41598-017-15467-6
- Yao X, Ye F, Zhang M et al (2020) In vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Clin Infect Dis [Online ahead of print]
- Gao J, Tian Z, Yang X (2020) Breakthrough: chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies. Biosci Trends 14, 72-73 https://doi.org/10.5582/bst.2020.01047
- Savarino A, Di Trani L, Donatelli I, Cauda R and Cassone A (2006) New insights into the antiviral effects of chloroquine. Lancet Infect Dis 6, 67-69 https://doi.org/10.1016/S1473-3099(06)70361-9
- Ducharme J and Farinotti R (1996) Clinical pharmacokinetics and metabolism of chloroquine. Focus on recent advancements. Clin Pharmacokinet 31, 257-274 https://doi.org/10.2165/00003088-199631040-00003
- Wang M, Cao R, Zhang L et al (2020) Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res 30, 269-271 https://doi.org/10.1038/s41422-020-0282-0
- Vincent MJ, Bergeron E, Benjannet S et al (2005) Chloroquine is a potent inhibitor of SARS coronavirus infection and spread. Virol J 2, 69 https://doi.org/10.1186/1743-422X-2-69
- Devaux CA, Rolain JM, Colson P and Raoult D (2020) New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19? Int J Antimicrob Agents [Online ahead of print]
- Savarino A., Boelaert JR, Cassone A, Majori G and Cauda R (2003) Effectd of chloroquine on viral infections: an old drug against today's diseases. Lancet Infect Dis 3, 722-727 https://doi.org/10.1016/S1473-3099(03)00806-5
- Wang LS, Wang YR, Ye DW and Liu QQ (2020) A review of the 2019 Novel Coronavirus (COVID-19) based on current evidence. Int J Antimicrob Agents [Online ahead of print]
- Gautret P, Lagier JC, Parola P et al (2020) Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. Int J Antimicrob Agents [Online ahead of print]
- Luke T, Kilbane E, Jackson J and Hoffman S (2006) Meta-analysis: convalescent blood products for Spanish influenza pneumonia: a future H5N1 treatment? Ann Intern Med 145, 599-609 https://doi.org/10.7326/0003-4819-145-8-200610170-00139
- Van Griensven J, Edwards T, de Lamballerie X et al (2016) Evaluation of convalescent plasma for Ebola virus disease in Guinea. N Engl J Med 374, 33-42 https://doi.org/10.1056/NEJMoa1511812
- Zhou B, Zhong N and Guan Y (2007) Treatment with convalescent plasma for influenza A (H5N1) infection. N Engl J Med 357, 1450-1451 https://doi.org/10.1056/NEJMc070359
- Mair-Jenkins J, Saavedra-Campos M, Baillie JK et al (2015) The effectiveness of convalescent plasma and hyperimmune immunoglobulin for the treatment of severe acute respiratory infections of viral etiology: a systematic review and exploratory meta-analysis. J Infect Dis 211, 80-90 https://doi.org/10.1093/infdis/jiu396
- Hung IF, To KK, Lee CK et al (2011) Convalescent plasma treatment reduced mortality in patients with severe pandemic influenza A (H1N1) 2009 virus infection. Clin Infect Dis 52, 447-456 https://doi.org/10.1093/cid/ciq106
- Cheng Z, Lu Y, Cao Q et al (2020) Clinical features and chest CT manifestations of coronavirus disease 2019 (COVID-19) in a single-center study in Shanghai, China. Am J Roentgenol [Online ahead of print]
- Ko JH, Seok H, Cho SY et al (2018) Challenges of convalescent plasma infusion therapy in Middle East respiratory coronavirus infection: a single centre experience. Antivir ther 23, 617-622 https://doi.org/10.3851/imp3243
- Lee PI and Hsueh PR (2020) Emerging threats from zoonotic coronaviruses-from SARS and MERS to 2019-nCoV. J Microbiol Immunol Infect [Online ahead of print]
- Chen L, Xiong J, Bao L and Shi Y (2020) Convalescent plasma as a potential therapy for COVID-19. Lancet Infect Dis 20, 398-400 https://doi.org/10.1016/s1473-3099(20)30141-9
- Bobati SS and Naik KR (2017) Therapeutic plasma exchange - an emerging treatment modality in patients with neurologic and non-neurologic diseases. J Clin Diagn Res 11, EC35-EC37
- Duan K, Liu B, Li C et al (2020) Effectiveness of convalescent plasma therapy in severe COVID-19 patients. Proc Natl Acad Sci U S A [Online ahead of print]
- Liu J, Cao R, Xu M et al (2020) Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro. Cell Discov 6, 16 https://doi.org/10.1038/s41421-020-0156-0